N/A
N=80
Surgical Treatment of Hip Fractures Under Peripheral Regional Anesthesia
Hip Fractures
Bottom Line
View on ClinicalTrials.gov: NCT04005404 ↗Enrolled (actual)
80
Serious AEs
47.4%
Results posted
Feb 2021
Primary outcome: Primary: Success Rate (Supplemental Medication) — 22; 20; 3 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Ropivacaine (sciatic nerve block) (Drug); Ropivacaine (lumbar plexus block L2-L4) (Drug); Ropivacaine (lumbar plexus block Th12-L1) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Helios Research Center
- Primary completion
- Jun 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Success Rate (Supplemental Medication) |
22; 20; 3 | — |
| PRIMARY Success Rate (Conversion to General Anesthesia) |
1; 3; 1 | — |
| SECONDARY Circulation Stability |
15; 15; 2 | — |
Summary
The study investigates whether treatment of proximal femoral fractures is possible using a peripheral regional anesthesia technique.
Eligibility Criteria
Inclusion Criteria
- proximal femoral fracture
- older then 18 years
- written informed consent
Exclusion Criteria
- local or systematic inflammation
- allergy to ropivacaine
- participate in other studies
- body mass index over 35
- periprosthetic fractures
Data sourced from ClinicalTrials.gov (NCT04005404). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.